Modulating growth factor signaling through precise and novel treatments
Our goal is to preserve and restore organ function in a range of acute and chronic conditions associated with tissue injury, inflammation, fibrosis and degeneration.
About Us
Follow us on our mission to treat fibrosis and restore organ function in multiple therapeutic areas
News & Events
PR
AGOMAB REPORTS POSITIVE PHASE 1 RESULTS WITH AGMB-129, A GI-RESTRICTED ALK5 INHIBITOR FOR FIBROSTENOSING CROHN’S DISEASE
February 2nd 2023
Agomab Therapeutics NV (‘Agomab’) today announced positive clinical results from its Phase 1 study evaluating AGMB-129, an oral gastro-intestinal (GI)-restricted small molecule kinase inhibitor of ALK5 (TGFβRI or ALK5), intended for the treatment of Fibrostenosing Crohn’s Disease (FSCD).
PR
Agomab Therapeutics Selected as One of Fierce Biotech's ``Fierce 15`` Companies of 2022
September 2022
“We are determined to improve the lives of patients through innovation. With a broad European footprint, we have built a leading company that combines transformative science with the commitment and passion of our experienced team, partners, and investors.”
-
Tim Knotnerus, Chief Executive Officer
